Brandon Twyford

DocwireNews

The phase 2 CITRIC trial, the first randomized study to use liquid biopsy to guide third-line rechallenge with cetuximab and irinotecan, shows encouraging results in patients with RAS wild-type (wt) metastatic colorectal cancer (mCRC). In these patients, where therapeutic options are usually limited, cetuximab rechallenge offers a much-needed alternative.
The study enrolled patients who had previously benefited from anti-EGFR therapy but experienced disease progression after second-line treatments. Using circulating tumor DNA (ctDNA) testing to select patients without RAS, BRAF V600E, or EGFR-ECD mutations, 58 participants were randomized to receive cetuximab plus irinotecan or the investigator’s choice of therapy, excluding anti-EGFR agents.
After a median follow-up of 5.1 months, the results indicated a significant advantage for those who received cetuximab rechallenge. The overall response rate (ORR) in the cetuximab arm was 9.7%, compared to 0% in the control group, while the disease control rate (DCR) was 71% in the cetuximab arm compared to 33.3% in the control arm (P=.008).
Treatment duration was also longer in the cetuximab group, with a median of 3.8 months compared to 2.1 months in the control arm. There were no significant differences in toxicity, except for an increased occurrence of rash in the cetuximab arm.
According to the study authors, “Our preliminary results demonstrate the effectiveness of cetuximab rechallenge in terms of ORR and DCR” for patients with RAS/BRAF/EGFR&#8211;ECD wild-type mCRC. These findings open the door to further research into liquid biopsy-guided rechallenge strategies, offering new avenues of treatment for a challenging patient population.

Molly Li, MBBS

Cecilia Brown

ESMO 2024 Highlights in Thoracic Oncology: Dr. Molly Li Shares Insights

ESMO Congress 2024

Rob Dillard

Stop to Save Your Life: Quitting Smoking Reduces the Risk of Atrial Fibrillation

Atrial Fibrillation

Jordana Jampel

Second-line nal-IRI: No PFS Improvement With S-1, Promising OS With 5-FU

Pancreatic Cancer

Latest News

Liquid Biopsy-Guided Cetuximab Rechallenge Demonstrates Improved Response, Disease Control Rates for mCRC

Colorectal Cancer

Cetuximab rechallenge guided by liquid biopsy improved response and disease control rates in RAS wild-type mCRC.

Liquid Biopsy-Guided Cetuximab Rechallenge Demonstrates Benefits for Metastatic Colorectal Cancer

About Us

Editorial Policy

Advertising

eNewsletters

Contribute

Contact Us

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

Mesothelioma

Non-Small Cell Lung Cancer

Small Cell Lung Cancer

Squamous Cell Lung Carcinoma

Lung Cancers Today

Atherosclerotic Disease

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

The Oncology Brothers

Rheumatology Rounds With Dr. Maheswaranathan

Healthcare Unfiltered

The Fellow on Call

Partners

Career Center

Expert Interviews

Subscribe